跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 3,542 条关于
“IDH-mutant astrocytoma”
全部
3,542
临床试验
2,267
药物
371
机构
18
资讯
886
10个月前
Orbus Therapeutics Reports Positive Phase 3 STELLAR Trial Results for Eflornithine in Recurrent IDH-Mutant Astrocytoma
去年
Eflornithine Plus Lomustine Improves Survival in IDH-Mutant Anaplastic Astrocytoma
去年
Eflornithine Plus Lomustine Improves Survival in IDH-Mutant Grade 3 Astrocytoma
去年
Eflornithine and Lomustine Combination Shows Survival Benefit in Recurrent Astrocytoma
8个月前
CATNON Trial Final Results Confirm Adjuvant Temozolomide Benefit in IDH-Mutant Anaplastic Glioma
去年
Eflornithine Combo Fails to Meet Primary Endpoint in Phase III Brain Cancer Trial
去年
FDA Approves Voranigo (Vorasidenib) as First Targeted Therapy for IDH-Mutant Glioma
上个月
First New Treatment for Rare Brain Cancer in 20 Years Added to Australia's PBS
2年前
FDA Approves Vorasidenib (Voranigo) for IDH-Mutant Glioma, Developed from Duke Neurosurgeon's Discovery
去年
European Regulators Recommend Approval of Vorasidenib for IDH-Mutant Grade 2 Glioma
第 1 页,共 89 页
上一页
下一页